VivoSeq
Other

Dexamethasone

0

Pipeline Programs↗

54

Active Trials↗

13

Companies Involved↗

Dexamethasone is an early-stage landscape with 0 programs across 13 companies. The most active players are Sanofi, Bristol-Myers Squibb, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

36/100

Mech. Concentration

N/A

Completion Rate

84/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalE

Eyegate Pharmaceuticals, Inc.

0 programs

PreclinicalEMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

315

clinical trials

Completed155 · 49%
Unknown status75 · 24%
Recruiting24 · 8%
Terminated22 · 7%
Active, not recruiting15 · 5%
Not yet recruiting12 · 4%
Other12 · 4%

Clinical Trials

Trial Activity

315 trials

Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study
Recruiting·—·Phase 2·NCT07334379·60 enrolled
Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
Recruiting·UUniversity College, London·Phase 2/3·NCT04061512·148 enrolled
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Recruiting·FFondazione Italiana Linfomi - ETS·Phase 2·NCT04915248·28 enrolled
Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia
Recruiting·RRadboud University Medical Center·Phase 4·NCT06624436·52 enrolled
Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants
Recruiting·—·Phase 1·NCT05387941·15 enrolled
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Recruiting·EEmory University·Phase 2·NCT06132685·200 enrolled
Short-course High-dose Prednisone and Dexamethasone in Children With ITP
Recruiting·FFujian Medical University Union Hospital·Phase 4·NCT05522465·608 enrolled
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Recruiting·—·Phase 1·NCT06863259·28 enrolled
TREAT-SC: Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in Children
Recruiting·SStarship Child Health, Te Toka Tumai Auckland·Phase 3·NCT06259006·80 enrolled
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Recruiting·EEmory University·Phase 2·NCT05208307·34 enrolled
IgIV Plus Prednisone vs High-dose Dexamethasone for ITP
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04968899·272 enrolled
The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia
Recruiting·—·Phase 2·NCT05732883·100 enrolled
Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07385131·300 enrolled
Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
Recruiting·—·N/A·NCT06984822·150 enrolled
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Recruiting·—·Phase 2·NCT04176718·43 enrolled
Page 1 of 21

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)